Compare AbbVie Inc (ABBV) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AngloGold Ashanti Limited — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while AngloGold Ashanti Limited trades at $79.58 (market cap $41.50B). The key difference: AbbVie Inc is far larger — about 10.8× AngloGold Ashanti Limited's market cap, and AngloGold Ashanti Limited pays the higher dividend (5.6%). Which is the better fit depends on your goals.
| ABBV | AU | |
|---|---|---|
Market Cap | $449.91B | $41.50B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $128.26 |
52-Week Low | $184.85 | $45.22 |
Enterprise Value | $513.38B | $40.63B |
Dividend Yield | 2.72% | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
AngloGold Ashanti (AU) trades at $82.01, down 3.12% on the day, near key support at $81. The stock shows strong fundamentals with 2025 revenue surging to $9.89B and net income reaching $2.64B, driving a robust 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS, while the company announced a $1.16 dividend and a share repurchase program. Technical indicators signal bearish momentum with RSI at 80.83 suggesting overbought conditions, but analyst consensus remains bullish with a $118 price target.
Outlook is positive due to explosive revenue growth, high profitability, and shareholder returns, but risks include gold price volatility and execution challenges. The stock offers value with a P/E of 12.34, though technical weakness may pressure near-term performance. Institutional sentiment is supportive with 64% buy ratings, but investors should monitor gold market dynamics and cost inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
